AR089553A1 - Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal - Google Patents
Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasalInfo
- Publication number
- AR089553A1 AR089553A1 ARP120101721A ARP120101721A AR089553A1 AR 089553 A1 AR089553 A1 AR 089553A1 AR P120101721 A ARP120101721 A AR P120101721A AR P120101721 A ARP120101721 A AR P120101721A AR 089553 A1 AR089553 A1 AR 089553A1
- Authority
- AR
- Argentina
- Prior art keywords
- oil
- testosterone
- testosterone gel
- intranasal
- lipophilic
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 34
- 229960003604 testosterone Drugs 0.000 title abstract 17
- 238000000034 method Methods 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000003921 oil Substances 0.000 abstract 3
- 235000019198 oils Nutrition 0.000 abstract 3
- 239000003981 vehicle Substances 0.000 abstract 3
- 206010002261 Androgen deficiency Diseases 0.000 abstract 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 229920002125 Sokalan® Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000003349 gelling agent Substances 0.000 abstract 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 abstract 2
- 210000003928 nasal cavity Anatomy 0.000 abstract 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 abstract 2
- 230000008719 thickening Effects 0.000 abstract 2
- 239000002562 thickening agent Substances 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 abstract 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 235000019489 Almond oil Nutrition 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- 239000004166 Lanolin Substances 0.000 abstract 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 235000019482 Palm oil Nutrition 0.000 abstract 1
- 235000019483 Peanut oil Nutrition 0.000 abstract 1
- 239000004264 Petrolatum Substances 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 239000008168 almond oil Substances 0.000 abstract 1
- 235000013871 bee wax Nutrition 0.000 abstract 1
- 239000012166 beeswax Substances 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 239000000828 canola oil Substances 0.000 abstract 1
- 235000019519 canola oil Nutrition 0.000 abstract 1
- 229960001631 carbomer Drugs 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 229960000541 cetyl alcohol Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003240 coconut oil Substances 0.000 abstract 1
- 235000019864 coconut oil Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 239000002385 cottonseed oil Substances 0.000 abstract 1
- 235000012343 cottonseed oil Nutrition 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229960005150 glycerol Drugs 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 abstract 1
- -1 ketostearyl alcohol Chemical compound 0.000 abstract 1
- 235000019388 lanolin Nutrition 0.000 abstract 1
- 229940039717 lanolin Drugs 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002540 palm oil Substances 0.000 abstract 1
- 239000012188 paraffin wax Substances 0.000 abstract 1
- 239000000312 peanut oil Substances 0.000 abstract 1
- 229940066842 petrolatum Drugs 0.000 abstract 1
- 235000019271 petrolatum Nutrition 0.000 abstract 1
- 229920000058 polyacrylate Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000010491 poppyseed oil Substances 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000003549 soybean oil Substances 0.000 abstract 1
- 235000012424 soybean oil Nutrition 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 239000001993 wax Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486324P | 2011-05-15 | 2011-05-15 | |
| US201161486634P | 2011-05-16 | 2011-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089553A1 true AR089553A1 (es) | 2014-09-03 |
Family
ID=46579248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101721A AR089553A1 (es) | 2011-05-15 | 2012-05-16 | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal |
| ARP120101720A AR086409A1 (es) | 2011-05-15 | 2012-05-16 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101720A AR086409A1 (es) | 2011-05-15 | 2012-05-16 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino |
Country Status (16)
| Country | Link |
|---|---|
| EP (3) | EP2709588B1 (enExample) |
| JP (9) | JP6152092B2 (enExample) |
| KR (10) | KR20190117803A (enExample) |
| CN (4) | CN110613679A (enExample) |
| AR (2) | AR089553A1 (enExample) |
| AU (11) | AU2012257490A1 (enExample) |
| BR (2) | BR112013029336B1 (enExample) |
| CA (3) | CA3034552C (enExample) |
| DK (1) | DK2714006T3 (enExample) |
| EA (1) | EA201391701A1 (enExample) |
| ES (1) | ES2859784T3 (enExample) |
| IL (2) | IL229400A0 (enExample) |
| MX (4) | MX395212B (enExample) |
| PL (1) | PL2714006T4 (enExample) |
| WO (2) | WO2012156822A1 (enExample) |
| ZA (2) | ZA201309264B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| MX395212B (es) * | 2011-05-15 | 2025-03-21 | Acerus Biopharma Inc | Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal. |
| US8971800B2 (en) * | 2011-05-31 | 2015-03-03 | Qualcomm Incorporated | Methods and apparatus for improving NFC activation and data exchange reporting mechanisms |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| US20140171918A1 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| WO2015054213A1 (en) * | 2013-10-07 | 2015-04-16 | Wotton Paul K | Hematocrit modulation through needle assisted jet injection of testosterone |
| EP3107547A4 (en) | 2014-02-19 | 2017-11-15 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
| WO2016123317A1 (en) * | 2015-01-28 | 2016-08-04 | Prometheon Pharma, Llc | Topical formulations of growth factors |
| CA2986444C (en) * | 2015-06-29 | 2023-10-24 | 480 Biomedical, Inc. | Implantable scaffolds for treatment of sinusitis |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
| ES2949053T3 (es) * | 2016-01-07 | 2023-09-25 | Viramal Ltd | Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR102487355B1 (ko) | 2016-04-25 | 2023-01-11 | 코스카 패밀리 리미티드 | 의료 전달 시스템 |
| EP3478270A4 (en) * | 2016-06-02 | 2019-11-27 | Acerus Labs, Inc. | HALF-RESISTANT AND VISCOUS LIQUID, NADAL FORMULATIONS OF CANNABINOIDS |
| KR102387241B1 (ko) * | 2016-06-03 | 2022-04-15 | 엠 이티 피 파마 아게 | 다공성 부형제를 갖는 비강용 약제학적 조성물 |
| HUE063346T2 (hu) | 2017-01-20 | 2024-01-28 | M et P Pharma AG | Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére |
| US10764951B2 (en) * | 2017-06-17 | 2020-09-01 | Lg Electronics Inc. | Registration method of user terminal in wireless communication system and apparatus therefor |
| KR102639913B1 (ko) | 2017-11-17 | 2024-02-23 | 코스카 패밀리 리미티드 | 유체 전달 매니폴드를 위한 시스템 및 방법 |
| AU2018371435B2 (en) * | 2017-11-27 | 2023-12-14 | Aska Pharmaceutical Co., Ltd. | Powder preparation for nasal administration |
| CN112020361A (zh) | 2018-02-02 | 2020-12-01 | 阿克罗斯生物制药公司 | 睾酮治疗方法 |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| US12544511B2 (en) | 2018-06-20 | 2026-02-10 | Koska Family Limited | Systems and methods for pre-filled dual-chamber medical agent delivery |
| CN108771622B (zh) * | 2018-07-11 | 2022-01-07 | 尹振图 | 一种自闭式针形滴嘴及眼药水瓶 |
| EP3870150A1 (en) | 2018-10-26 | 2021-09-01 | Viramal Limited | Mucoadhesive gel composition |
| US20200170962A1 (en) | 2018-11-30 | 2020-06-04 | F. Markus Leweke | Nasal cannabidiol compositions |
| ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
| WO2020118437A1 (en) * | 2018-12-14 | 2020-06-18 | Acerus Biopharma Inc. | Active ester derivatives of testosterone, compositions and uses thereof |
| USD1052082S1 (en) | 2020-06-01 | 2024-11-19 | Koska Family Limited | Sealed fluid container |
| CN112121049B (zh) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用 |
| EP4247332B1 (en) * | 2020-11-19 | 2026-04-22 | Acousia Therapeutics GmbH | Non-aqueous gel composition |
| GB202307501D0 (en) * | 2023-05-19 | 2023-07-05 | Lawley Pharmaceuticals Pty Ltd | Process for preparing dispensable testosterone cream |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| DE4214953C2 (de) | 1992-05-06 | 1995-05-18 | Arrowdean Ltd | Arzneimittel zur Erhöhung des Testosteronspiegels |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5576071A (en) | 1994-11-08 | 1996-11-19 | Micron Technology, Inc. | Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds |
| JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
| DK1510213T3 (da) * | 1997-11-10 | 2009-03-23 | Strakan Int Ltd | Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| WO2005039531A1 (en) * | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| JP2005505587A (ja) * | 2001-10-12 | 2005-02-24 | シーエヌエス・インコーポレーテッド | 含水性の点鼻ゲル及びその塗布装置 |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| ES2258694T3 (es) * | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| KR101217680B1 (ko) * | 2004-12-09 | 2013-01-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 산을 사용한 글루코코르티코이드 에스테르의 안정화 |
| EP1896038B1 (en) * | 2005-06-03 | 2016-11-09 | Acrux DDS Pty Ltd | Method and composition for testosterone transdermal delivery |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| CN101099742A (zh) * | 2006-07-06 | 2008-01-09 | 上海富海科申药业有限公司 | 能够减少皮肤刺激的睾酮凝胶制剂 |
| CA2664427C (en) * | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| WO2008116825A2 (en) * | 2007-03-23 | 2008-10-02 | Unimed Pharmaceuticals, Llc | Compositions and method for treating pediatric hypogonadism |
| US8507467B2 (en) * | 2007-09-20 | 2013-08-13 | Shiseido Company, Ltd. | Transdermally absorbable preparation |
| ES2547339T3 (es) * | 2007-11-13 | 2015-10-05 | Curadis Gmbh | Esteroides C-19 para usos terapéuticos específicos |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| MX395212B (es) * | 2011-05-15 | 2025-03-21 | Acerus Biopharma Inc | Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal. |
-
2012
- 2012-05-15 MX MX2020008599A patent/MX395212B/es unknown
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/en not_active Ceased
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh not_active Expired - Fee Related
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Ceased
- 2012-05-15 CA CA3034552A patent/CA3034552C/en active Active
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 PL PL12748245T patent/PL2714006T4/pl unknown
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/en not_active Ceased
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/en active Active
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko not_active Ceased
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Ceased
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/en active Active
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko not_active Ceased
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Ceased
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 KR KR1020247037387A patent/KR20240162608A/ko active Pending
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Ceased
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 CA CA2836405A patent/CA2836405C/en active Active
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/en not_active Withdrawn
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-15 CA CA2836398A patent/CA2836398C/en active Active
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 MX MX2019003340A patent/MX374398B/es active IP Right Grant
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active Active
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active Active
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko not_active Ceased
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
-
2013
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
-
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
-
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
-
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
-
2024
- 2024-08-23 AU AU2024216312A patent/AU2024216312A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
| CR20240233A (es) | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer | |
| HK1243942A1 (zh) | 舒尼替尼制剂及其在治疗青光眼中的使用方法 | |
| MX2021008358A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| ES3063344T3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| MX389700B (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| UY32582A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| MX2015016277A (es) | Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa. | |
| PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
| UY31294A1 (es) | Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| BRPI1015539A2 (pt) | composições e métodos para tratamento de queimaduras | |
| UY36207A (es) | Inhibidores de la syk | |
| JP2014510042A5 (enExample) | ||
| MX387113B (es) | Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. | |
| AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
| CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| JP2016501205A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |